Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Zibing, Wang"'
Autor:
Huacong Sun, Qing Yang, Jianlin Wang, Mingchao Ding, Mouyang Cheng, Lei Liao, Chen Cai, Zitao Chen, Xudan Huang, Zibing Wang, Zhi Xu, Wenlong Wang, Kaihui Liu, Lei Liu, Xuedong Bai, Ji Chen, Sheng Meng, Lifen Wang
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Color centers, arising from zero-dimensional defects, exploit quantum confinement to access internal electron quantum degrees of freedom, holding potential for quantum technologies. Despite intensive research, the structural origin of many c
Externí odkaz:
https://doaj.org/article/5c626453648f4b1c96e05365ebcc92d7
Autor:
Han Li, Shumin Yuan, Han Wu, Yajie Wang, Yichen Ma, Xiance Tang, Xiaomin Fu, Lingdi Zhao, Benling Xu, Tiepeng Li, Peng Qin, Hongqin You, Lu Han, Zibing Wang
Publikováno v:
Cancer Innovation, Vol 3, Iss 6, Pp n/a-n/a (2024)
Abstract Background This study evaluated the efficacy and safety of low‐dose anlotinib combined with immune checkpoint inhibitors as second‐line or later treatment for extensive‐stage small cell lung cancer (ES‐SCLC). Methods The study includ
Externí odkaz:
https://doaj.org/article/2db760d7a5ae4f9b87d94ddb09d2d50a
Autor:
Xiaomin Fu, Peng Qin, Fanghui Li, Huifang Zhu, Hongqin You, Yong Zhang, Benling Xu, Tiepeng Li, Fang Zhang, Lu Han, Lingdi Zhao, Baozhen Ma, Zibing Wang, Quanli Gao
Publikováno v:
Immunity & Ageing, Vol 20, Iss 1, Pp 1-12 (2023)
Abstract Background Although the concept of declined immune function associated with cancer has been accepted extensively, real-world clinical studies focusing on analysis of the peripheral blood immune changes underlying ageing, immunity and cancer
Externí odkaz:
https://doaj.org/article/27f9c2859c7a49068713dcc2c79c1817
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Immunotherapy is currently the most promising clinical treatment for lung cancer, not only revolutionizing second-line therapy but now also approved for first-line treatment. However, its clinical efficiency is not high and not all patients benefit f
Externí odkaz:
https://doaj.org/article/b4080cd424e542398139a2a652370484
Autor:
Bin Wu, Lihong Huang, Lin Chen, Xiaoling Wang, Xiaomin Zeng, Chengjie Xiong, Hedan Kou, Chenwei Wang, Hanli Sun, Shangyuan Liu, Jingyao Li, Zibing Wang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background E6 and E7 oncoproteins are considered ideal antigens of T cell therapy for human papillomavirus (HPV)-related cancers. However, little is known about the epitopes of E6 and E7 presented by HLA-A*11:01, one of the most prevalent HLA types g
Externí odkaz:
https://doaj.org/article/a7cd9428ee63443faaf3f78fb8e43f2c
Autor:
Baozhen Ma, Yu Zhou, Yiman Shang, Yong Zhang, Benling Xu, Xiaomin Fu, Jindong Guo, Yonghao Yang, Fang Zhang, Mengyuan Zhou, Hao Huang, Fanghui Li, Hongwei Lin, Lingdi Zhao, Zibing Wang, Quanli Gao
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Despite recent progress in treating advanced non-small cell lung cancer, clinical intervention in extensive-stage small-cell lung cancer (ES-SCLC) remains stagnant. The purpose of this study was to evaluate the clinical efficacy of cytokine-induced k
Externí odkaz:
https://doaj.org/article/fa0f124aa8244db3847402348736cf72
Autor:
Hao Huang, Ling Peng, Bicheng Zhang, Brian G. Till, Yonghao Yang, Xiaojie Zhang, Lingdi Zhao, Xiaomin Fu, Tiepeng Li, Lu Han, Peng Qin, Lin Chen, Xiang Yan, Yang Liu, Wenkang Wang, Zhenlong Ye, Hongle Li, Quanli Gao, Zibing Wang
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
PurposeThis study determined the efficacy of low-dose gemcitabine combined with programmed death-1 (PD-1) inhibitors for treating multiple malignancies, providing a cost-effective and safe treatment option.Study DesignThis study included 61 patients
Externí odkaz:
https://doaj.org/article/518d588a572e4de6bd0b5df295c880ed
Autor:
Lingdi Zhao, Tiepeng Li, Yongping Song, Yonghao Yang, Baozhen Ma, Yong Zhang, Yiman Shang, Benling Xu, Jindong Guo, Peng Qin, Lu Han, Xiaomin Fu, Hongwei Lin, Liang Liu, Xiubao Ren, Zibing Wang, Quanli Gao
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
Background and ObjectiveThe results of the CheckMate 025 trial established the status of nivolumab in the second-line treatment of metastatic renal cell carcinoma (mRCC), with an objective response rate (ORR) of 25% and a complete response (CR) rate
Externí odkaz:
https://doaj.org/article/243413ee34b54048850fc83d50d4b9e3
Autor:
Wenqun Xing, Lingdi Zhao, Yan Zheng, Baoxing Liu, Xianben Liu, Tiepeng Li, Yong Zhang, Baozhen Ma, Yonghao Yang, Yiman Shang, Xiaomin Fu, Guanghui Liang, Dongfeng Yuan, Jinrong Qu, Xiaofei Chai, He Zhang, Zibing Wang, Hongwei Lin, Liang Liu, Xiubao Ren, Jiangong Zhang, Quanli Gao
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundThere is no standard neoadjuvant therapy for locally advanced esophageal cancer in China. The role of neoadjuvant chemotherapy plus immunotherapy for locally advanced esophageal cancer is still being explored.MethodsThis open-label, randomi
Externí odkaz:
https://doaj.org/article/00334cde9e1b4ce68205dfd247332859
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Owing to broad and notable clinical anti-tumor activity, anti-programmed cell death-1 (PD-1)/anti-programmed cell death-ligand 1 (PD-L1) antibodies have been indicated for almost all types of cancer, and form a part of the current standard of care. H
Externí odkaz:
https://doaj.org/article/13811c5ae6b64cd3ba6de3180ab064e8